ARCHIVES

Congressional Committee, SEC Probe ImClone’s Statements To Shareholders.

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

Mendelsohn Defends ImClone’s Actions And His Role In Development of C225

October 18, 2002

BSA Approves Trial of Carbon Ion Therapy, Extends EDRN And Provocative Questions

July 4, 2014

Hammer Agrees To Bush Request for FDA Probe

July 15, 1988

NCI’s Rosenberg Confirms 2002 Immunotherapy Results

April 29, 2005

Pinkel Corrects Report On ALL – Two Drugs Are Better Than One

April 21, 1978

Skipper’s Impact: Drugs Curing 40,000 a Year

March 27, 1981